Scott Z. Fields, MD, Bayer Pharmaceuticals explains Oncogenic Signaling with Larotrectinib | LOXO-195 for Those Progressed on TRK-Inhibitor at Annual Meeting 2018
oncogenic signaling, larotrectinib & #124, loxo-195, trk-inhibitor, annual meeting 2018, bayer pharmaceuticals
Advertisement